Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)

Elizabeth J. Bell, Paul A. Decker, Michael Y. Tsai, James S. Pankow, Naomi Q. Hanson, Christina L. Wassel, Nicholas B. Larson, Kevin P. Cohoon, Matthew J. Budoff, Joseph F. Polak, James H. Stein, Suzette J. Bielinski

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Background and aims: Hepatocyte growth factor (HGF) has previously been associated with risk of stroke, coronary heart disease, and atherosclerosis. We hypothesized that higher circulating HGF is associated with greater progression of measures of atherosclerosis: coronary artery calcium (CAC) and carotid plaque. Methods: Participants aged 45–84 years from the prospective cohort study Multi-Ethnic Study of Atherosclerosis had HGF measured at baseline (between 2000 and 2002) and were followed for progression of atherosclerosis for up to 12 years. CAC was measured at all five exams using the Agatston method. Mixed-effects models were used to examine the association of HGF and CAC progression among 6695 participants with available data. Relative risk regression was used to assess the association between HGF and new or additional carotid plaque between exams 1 and 5 in 3400 participants with available data. All point estimates were adjusted for potential confounding variables. Results: Each standard deviation higher HGF at baseline was associated with 2.9 Agatston units/year greater CAC progression (95% CI: 1.6–4.2, p < 0.0001), and the magnitude of this association differed by race/ethnicity (p value for interaction by race = 0.003). Each standard deviation higher HGF at baseline was associated with a 4% higher risk of new or additional carotid plaque (95% CI: 1.01–1.08, p = 0.005). Conclusions: Higher levels of HGF were significantly associated with greater progression of atherosclerosis in this large and diverse population. Circulating HGF continues to show promise as a potential clinical biomarker for cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)162-167
Number of pages6
JournalAtherosclerosis
Volume272
DOIs
StatePublished - May 2018

Bibliographical note

Funding Information:
Dr. Bell is supported by the NIH T32 Training Grant HL07111-40 . This study was supported by the National Institutes of Health (NIH; grant numbers N01 HC95159 , N01 HC95160 , N01 HC95161 , N01 HC95162 , N01 HC95163 , N01 HC95164 , N01 HC95165 , N01 HC95166 , N01 HC95167 , and N01 HC95168 ); National Heart, Lung, and Blood Institute (NHLBI) at NIH (grant number N01 HC95169 ); and National Center for Research Resources at NIH (grant numbers UL1 TR000040 and UL1 TR001079 ). Funding for adhesion protein levels was provided by the NHLBI at NIH (grant number R01 HL98077 ).

Funding Information:
We thank the other investigators, the staff, and the participants of the MESA study for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org . MESA is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators.

Publisher Copyright:
© 2018 Elsevier B.V.

Keywords

  • Atherosclerosis
  • Cardiovascular risk factors
  • Carotid plaque
  • Coronary artery calcium
  • Hepatocyte growth factor

Fingerprint

Dive into the research topics of 'Hepatocyte growth factor is associated with progression of atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA)'. Together they form a unique fingerprint.

Cite this